NCT04868292CompletedPhase 1
A Phase 1, Single-Center, Open-Label Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Intravenous Administration of SPR206 in Healthy Volunteers
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Spero Therapeutics
- Enrollment
- 34
- Locations
- 1
- Primary Endpoint
- Maximum observed concentration (Cmax) for ELF, AM, and plasma
Study Overview
Brief Summary
To evaluate the intrapulmonary pharmacokinetics (PK), including epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations, of SPR206 as well as plasma concentrations of SPR206 in healthy adult volunteers.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Non-smoker for at least 12 months prior to screening for the study
- •BMI ≥ 18.5 and ≤ 32 (kg/m2) and weight between 55.0 and 100.0 kg (both inclusive)
- •Medically healthy without clinically significant abnormalities as assessed by the Investigator based on screening medical history, physical examination, vital signs, 12-lead ECG, hematology, biochemistry, coagulation, and urinalysis
- •Forced expiratory volume in 1 second (FEV1) of at least 80% of predicted value at screening
- •Ability and willingness to abstain from alcohol, caffeine, xanthine-containing beverages or food from 48 hours prior to study drug administration until discharge from the clinical unit
- •If male, must agree to use a condom and have a non-pregnant female partner of childbearing potential agree to use a highly effective method of contraception
- •If female, must be of non-childbearing potential or, if female of childbearing potential, a willingness to abstain from sexual activity or agree to use a high effective method of contraception that could lead to pregnancy
- •Other inclusion criteria per protocol
Exclusion Criteria
- •History or presence of significant oncologic, cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, vascular or neurological disease, including any acute illness or surgery within the past 3 months determined by the Investigator to be clinically relevant
- •Recent history (within 6 months) of known or suspected Clostridium difficile infection
- •History of seizure disorders
- •Positive urine drug, alcohol or cotinine testing at screening or check-in (Day -1)
- •Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C antibodies (HCV Ab)
- •Positive testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at screening or prior to first dosing
- •Presence of the following symptoms at screening or within 28 days prior to screening or check-in (Day -1):
- •Fever, chills or sweats (temperature of 38 °C / 100.4 °F or higher)
- •Difficulty breathing
- •Sore throat
- •New or recent loss of taste or smell
- •Nausea, vomiting or diarrhea
- •Close contact with anyone who tested positive for SARS-CoV-2 infection within 28 days prior to screening or check-in (Day -1)
- •Electrocardiogram (ECG) with QTcF interval duration equal or greater than 450 msec for males and 470 msec for females
- •Subjects who have any of the following abnormalities on laboratory values at screening or Check-In including:
- •White blood cell count < 3,000/mm3, hemoglobin < 11g/dL
- •Absolute neutrophil count ≤ 2,000/mm3, platelet count <120,000/mm3
- •alanine aminotransferase (ALT) OR aspartate aminotransferase (AST) greater than the upper limit of normal (ULN) for the reference laboratory
- •History of substance abuse or alcohol abuse
- •Use of prescription medicine & tobacco/nicotine or marijuana-containing products
- •A female who is pregnant or breastfeeding
- •Other exclusion criteria per protocol
Arms & Interventions
SPR206
Experimental
Healthy subjects meeting eligibility criteria will receive a total of three 100 mg SPR206 intravenous doses administered every 8 hours.
Intervention: SPR206 (Drug)
Outcomes
Primary Outcomes
Maximum observed concentration (Cmax) for ELF, AM, and plasma
Time Frame: 8 hours after the start of the third study drug IV infusion
Area under the concentration-time curve from time 0 to 8 hours (AUC0-8) for ELF, AM, and plasma
Time Frame: 8 hours after the start of the third study drug IV infusion
Minimum concentration (Cmin) for ELF, AM, and plasma
Time Frame: 8 hours after the start of the third study drug IV infusion
Time to the maximum observed concentration (Tmax) for ELF, AM, and plasma
Time Frame: 8 hours after the start of the third study drug IV infusion
Secondary Outcomes
- Incidence of abnormal vital sign assessments - respiratory rate(Day -1 to Day 7)
- Incidence of Treatment-Emergent Adverse Events(Day -1 to Day 7)
- Incidence of abnormal vital sign assessments - blood pressure(Day -1 to Day 7)
- Incidence of abnormal vital sign assessments - body temperature(Day -1 to Day 7)
- Incidence of abnormal vital sign assessments - heart rate(Day -1 to Day 7)
- Incidence of abnormal ECG assessments - PR, RR, QRS, QT and QTcF interval(Day -1 to Day 7)
- Incidence of abnormal physical exam assessments(Day -1 to Day 7)
- Incidence of abnormal safety laboratory assessments(Day -1 to Day 7)
- Incidence of abnormal ECG assessments - heart rate(Day -1 to Day 7)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.Healthy VolunteerNCT05955586Spero Therapeutics33
Completed
Phase 1
Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy SubjectsHealthy SubjectsNCT04951505Venatorx Pharmaceuticals, Inc.30
Completed
Phase 1
Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking VolunteersHealthy VolunteersNCT04710407Spero Therapeutics30
Completed
Phase 1
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy SubjectsHepatic ImpairmentNCT03369002CymaBay Therapeutics, Inc.32
Completed
Phase 1
Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human SubjectsIntrapulmonary Pharmacokinetics of WCK 2349NCT02253342Wockhardt30